ArticleViruses2016
Monitoring of Anti-Hepatitis E Virus Antibody Seroconversion in Asymptomatically Infected Blood Donors: Systematic Comparison of Nine Commercial Anti-HEV IgM and IgG Assays.
Article in Viruses, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 63 citations in OpenAlex.
- Seroprevalence of hepatitis E virus in risk populations and blood donors in a referral hospital in the south of Brazil.Scientific reports · 2021Trial
- Multi-dimensional surveillance of hepatitis E: a 20-year observational analysis in Shanghai, China.BMC infectious diseases · 2026Observational
- Seroprevalence and Risk Factors for Hepatitis E Virus in a Metropolis of Northeastern Brazil: A Population-Based Survey.Zoonoses and public health · 2026Article
- Seroprevalence of Hepatitis A Virus (HAV) and Hepatitis E Virus (HEV) Among Blood Donor Candidates in Salvador, Bahia, Brazil.Viruses · 2026Article
- Increase in HEV IgG Seroprevalence During the Past Years in Southern France.Journal of medical virology · 2025Article
- Long-lasting IgM and declining IgG levels: a serologic 5-year follow-up study in healthy blood donors infected with hepatitis E virus.Medical microbiology and immunology · 2025Article
- Cost-Effectiveness Analysis of Hepatitis E Vaccination Strategies for Swine Workers.Transboundary and emerging diseases · 2025Article
- Geospatial distribution of Hepatitis E seroprevalence in Nepal, 2021.PLoS neglected tropical diseases · 2024Article
- Performance Comparison of Four Hepatitis E Antibodies Detection Methods.Microorganisms · 2024Article
- Assessment of the Diagnostic Performance of Fully Automated Hepatitis E Virus (HEV) Antibody Tests.Diagnostics (Basel, Switzerland) · 2024Article
- Asymptomatic arbovirus and campylobacter infections in German travelers to Asia.Archives of virology · 2023Article
- Hepatitis E Virus (HEV) Infection in Hemodialysis Patients: A Multicenter Epidemiological Cohort Study in North-Eastern Greece.Pathogens (Basel, Switzerland) · 2023Article
- Higher Risk of HEV Transmission and Exposure among Blood Donors in Europe and Asia in Comparison to North America: A Meta-Analysis.Pathogens (Basel, Switzerland) · 2023Review
- Calibrating Hepatitis E Virus Serological Assays Using Asymptomatic Specimens Obtained in Japan.Microbiology spectrum · 2022Article
- Article
- Hepatitis E Infection in Solid Organ Transplant Recipients in Turkey.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Article
- Hepatitis E virus as a trigger for Guillain-Barré syndrome.BMC neurology · 2021Article
- Hepatitis E Infection in a Longitudinal Cohort of Hepatitis C Virus and HCV/HIV Coinfected Persons.AIDS research and human retroviruses · 2021Article
- Evaluation of a Novel CLIA Monotest Assay for the Detection of Anti-Hepatitis E Virus-IgG and IgM: A Retrospective Comparison with a Line Blot and an ELISA.Pathogens (Basel, Switzerland) · 2021Article
- Cell Cultures for Virology: Usability, Advantages, and Prospects.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnosis of hepatitis E virus (HEV) is usually determined serologically by detection of the presence of immunoglobulin (Ig)M antibodies or rising anti-HEV IgG titers. However, serological assays have demonstrated a significant variation in their sensitivities and specificities. In this study, we present the systematic comparison of different immunological anti-HEV assays using complete seroconversion panels of 10 virologically confirmed HEV genotype 3 infected individuals. Assay sensitivities were further evaluated by testing serially diluted World Health Organization (WHO) reference reagent for hepatitis E virus antibody and one patient sample infected with HEV genotype 3. Anti-HEV IgM and IgG antibody presence was determined using the immunological assays Wantai HEV IgM/IgG enzyme-linked immunosorbent assay (ELISA) (Sanbio, Uden, The Netherlands), recomWell HEV IgM/IgG (Mikrogen, Neuried, Germany), HEV IgM ELISA 3.0, HEV ELISA, HEV ELISA 4.0, Assure HEV IgM Rapid Test (all MP Biomedicals Europe, Illkirch Cedex, France) and Anti-HEV ELISA (IgM/IgG, Euroimmun, Lübeck, Germany). The assays showed differences regarding their analytical and diagnostic sensitivities, with anti-HEV IgM assays (n = 5) being more divergent compared to anti-HEV IgG (n = 4) assays in this study. Considerable variations were observed particularly for the detection period of IgM antibodies. This is the first study systematically characterizing serologic assays on the basis of seroconversion panels, providing sample conformity for a conclusive comparison. Future studies should include the assay comparison covering the four different genotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.